Cargando…

Antihypertensive drugs and risk of COVID-19?

Detalles Bibliográficos
Autor principal:	Brown, Joshua D
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2020
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7194728/ https://www.ncbi.nlm.nih.gov/pubmed/32222168 http://dx.doi.org/10.1016/S2213-2600(20)30158-2

Ejemplares similares

Antihypertensive drugs and risk of COVID-19?
por: Lo, Kevin Bryan, et al.
Publicado: (2020)

Antihypertensive drugs in COVID-19 infection
por: Pinto-Sietsma, Sara-Joan, et al.
Publicado: (2020)

Antihypertensive treatment with ACEI/ARB of patients with COVID-19 complicated by hypertension
por: Li, Gang, et al.
Publicado: (2020)

Antihypertensive drugs and risk of COVID-19?
por: Tignanelli, Christopher J, et al.
Publicado: (2020)

Association between serum homocysteine and arterial stiffness: role of antihypertensive drugs
por: Varol, Ercan
Publicado: (2014)

Antihypertensive drugs and risk of COVID-19? – Authors' reply
por: Fang, Lei, et al.
Publicado: (2020)

The reduction in CVD outcomes with antihypertensives: A mandatory goal
por: Gupta, Rajeev
Publicado: (2017)

Antihypertensives: sex differences in risk of COVID-19
Publicado: (2021)

Lack of association of antihypertensive drugs with the risk and severity of COVID-19: A meta-analysis
por: Ren, Lu, et al.
Publicado: (2021)

Repurposed GI Drugs in the Treatment of COVID-19
por: Aguila, Enrik John T., et al.
Publicado: (2020)

COVID-19… What are drugs and strategies now?
por: Bellini, Valentina, et al.
Publicado: (2021)

Antihypertensive Drugs and COVID-19 Risk: A Cohort Study of 2 Million Hypertensive Patients
por: Semenzato, Laura, et al.
Publicado: (2021)

Repurposing existing drugs for COVID-19: an endocrinology perspective
por: Cadegiani, Flavio A.
Publicado: (2020)

Metabolomics to Predict Antiviral Drug Efficacy in COVID-19
por: Migaud, Marie, et al.
Publicado: (2020)

Ethnic disparities in COVID-19: increased risk of infection or severe disease?
por: Pan, Daniel, et al.
Publicado: (2021)

COVID-19 vaccines in high-risk ethnic groups
por: D'Souza, Rashmi S, et al.
Publicado: (2021)

Risk of COVID-19 for patients with cancer
por: Xia, Yang, et al.
Publicado: (2020)

Risk of COVID-19 for patients with cancer
por: Wang, Hanping, et al.
Publicado: (2020)

Coronavirus disease 2019 (COVID-19) and anti-rheumatic drugs
por: Georgiev, Tsvetoslav
Publicado: (2020)

The effects of the COVID-19 pandemic on the use of the performance-enhancing drugs
por: Negro, Francesca, et al.
Publicado: (2021)

Measuring Adherence to Antihypertensive Drug Therapy
por: D'Souza, Anna
Publicado: (2004)

Individualization of Antihypertensive Drug Treatment
por: Mancia, Giuseppe, et al.
Publicado: (2013)

Sympathetic modulation by antihypertensive drugs
por: Katsurada, Kenichi, et al.
Publicado: (2021)

COVID-19, rheumatic diseases and immunosuppressive drugs: an appeal for medication adherence
por: Venerito, Vincenzo, et al.
Publicado: (2020)

Efficacy of Antibodies and Antiviral Drugs against Covid-19 Omicron Variant
por: Takashita, Emi, et al.
Publicado: (2022)

Diversity of mechanism of action of psychotropic drugs in their anti-COVID-19 properties
por: Stip, Emmanuel, et al.
Publicado: (2021)

Nebulization and COVID-19: Is the risk of spread actual?
por: Thibon, Christophe, et al.
Publicado: (2022)

The Independent Effect of COVID-19 Vaccinations and Air Pollution Exposure on Risk of COVID-19 Hospitalizations in Southern California
por: Chen, Zhanghua, et al.
Publicado: (2022)

Association of Antihypertensive Agents with the Risk of In-Hospital Death in Patients with Covid-19
por: Chouchana, Laurent, et al.
Publicado: (2021)

Counting the global COVID-19 dead
por: Jha, Prabhat, et al.
Publicado: (2022)

Antihypertensive Drugs and the Risk of Cancer: A Nationwide Cohort Study
por: Cho, In-Jeong, et al.
Publicado: (2021)

The emergence of powerful oral anti-COVID-19 drugs in the post-vaccine era
por: Fan, Huahao, et al.
Publicado: (2022)

COVID-19 drug research and the cohort multiple randomised controlled trial design
por: Dal-Ré, Rafael
Publicado: (2022)

Severe bullous drug reaction after COVID‐19 mRNA vaccination
por: Irmer, Marie Luise, et al.
Publicado: (2022)

Work a key determinant in COVID-19 risk
por: Marinaccio, Alessandro, et al.
Publicado: (2020)

COVID-19: the risk of respiratory techniques in healthcare workers
por: Torres-Castro, Rodrigo, et al.
Publicado: (2020)

Is nutrition the forgotten risk factor in COVID-19 infection?()
por: Carretero Gómez, J., et al.
Publicado: (2021)

The risk of COVID-19 in survivors of domestic violence and abuse
por: Chandan, Joht Singh, et al.
Publicado: (2021)

Preprocedural COVID-19 Testing for High Risk Procedures
por: Palaniswamy, Haritha, et al.
Publicado: (2021)

Fluvoxamine for the treatment of COVID-19
por: Dodds, Michael G, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_korrbusc9qus7p7ugmpka4nsqh